MIRD dose estimate report No. 20: Radiation aBsorbed-dose estimates for 111In-And 90Y-ibritumomab Tiuxetan

Journal of Nuclear Medicine

Volumn 50, Issue 4, 2009, Pages 644-652

  Fisher, Darrell R ^a   Shen, Sui ^b   Meredith, Ruby F ^b  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

111in ibritumo Mabtiuxetan; 90y ibritumomab tiuxetan; Antibody; Dosimetry; Lymphoma; MIRD dose estimate report; Radiopharmaceutical; Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; DOSE CALCULATION; DOSIMETRY; DRUG DEGRADATION; DRUG RETENTION; DRUG UPTAKE; FEMALE; HEART; HUMAN; INTESTINE WALL; KIDNEY; LIVER; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; NONHODGKIN LYMPHOMA; ORGAN SIZE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION RESPONSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA; SCINTISCANNING; SPLEEN; TESTIS; THERAPY EFFECT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BODY BURDEN; HUMANS; INDIUM RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; RADIATION DOSAGE; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 63849343663     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.057331     Document Type: Article

References (33)

1. Wiseman GA, Leigh BR, Erwin WD, et al. Radiation dosimetry results from a phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2003;18:165-178.
2. Wiseman GA, Leigh BR, Erwin WD, et al. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. Cancer Biother Radiopharm. 2003;18:253-258.
3. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
4. Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer. 2002;94(4, suppl):1349-1357.
5. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39:181-194.
6. Zevalin® prescribing information [package insert]. Seattle, WA: Cell Therapeutics, Inc.; 2008. Available at: www.zevalin.com/pdf/Zevalin-PI-website. pdf. Also available at: http://www.fda.gov/cder/foi/label/2002/ibriide021902LB. pdf. Accessed February 20, 2009.
7. 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med. 2007;48:1871-1879.
8. 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2008;23:53-64.
9. Stabin M, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
10. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. Rev ed. Reston, VA: Society of Nuclear Medicine; 1999.
11. 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a highaffinity chelator for yttrium [abstract]. Proc Am Assoc Cancer Res. 1999; 40:574.
12. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635-2642.
13. Stabin MG, da Luz LC. New decay data for internal and external dose assessment. Health Phys. 2002;83:471-475.
14. Bray L, Wester DW, inventors; Battelle Memorial Institute, assignee. Method of separation of yttrium-90 from strontium-90. U.S. patent 5,512,256. April 30,1996.
15. Khazaeli MB. Quantitation of mouse monoclonal antibody and human antimouse antibody response in serum of patients. Hybridoma. 1989;8:231-239.
16. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-591.
17. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
18. DeNardo GL, DeNardo SJ, Macey DJ, Mills SL. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: Srivastava SC, ed. Radiolabeled Monoclonal Antibodies for Imaging and Therapy. New York, NY: Plenum; 1988:293-310.
19. Eary JF, Appelbaum FL, Durack L, Brown P. Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med Phys. 1989;16:382-387.
20. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999; 40(suppl):37S-61S.
21. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;03:253-255.
22. Shen S, Forero A, LoBuglio AF, et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med. 2005;46:642-651.
23. 90Y-zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. EurJNucl Med. 2000;27:766-777.
24. International Commission on Radiological Units and Measurements (ICRU). Tissue Substitutes in Radiation Dosimetry (Report 44). Bethesda, MD: ICRU; 1989. Available at: http://www.icm.org/index2.php?option=com-content&do-pdf = 1&id=80. Accessed February 20, 2009.
25. Lim S, DeNardo GL, DeNardo DA, O'Donnell RT, Yuan A, DeNardo SJ. Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med. 1997;38:1749-1753.
26. Conti PS, White C, Pieslor P, et al. The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med. 2005;46:1812-1818.
27. Nettleton JS, Lawson RS, Prescott MC, Morris ID. Uptake, localization, anddosimetry of 111In and 201Tl in human testes. J Nucl Med. 2004;45:138-146.
28. International Commission on Radiological Protection (ICRP). Report of the Task Group on Reference Man. ICRP Publication No. 23. Oxford, England: Pergamon Press; 1975.
29. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
30. Shen S, Meredith R, Duan J, et al. Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein. Cancer Biother Radiopharm. 2005; 20:110-118.
31. Mardirossian G, Brill AB, Harwood SJ, et al. Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18. J Nucl Med. 1998;39:671-676.
32. Mardirossian G, Brill AB, Dwyer KM, et al. Radiation absorbed dose from indium-111-CYT-356. J Nucl Med. 1996;37:1583-1588.
33. 111In-labelled platelets in organs. Eur J Nucl Med. 1982;7:80-84.